Cargando…

Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans

Detalles Bibliográficos
Autores principales:	Mayr, Florian B., Talisa, Victor B., Shaikh, Obaid, Yende, Sachin, Butt, Adeel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849183/ https://www.ncbi.nlm.nih.gov/pubmed/35139265 http://dx.doi.org/10.1056/NEJMc2200415

Ejemplares similares

Comparative COVID-19 Vaccine Effectiveness Over Time in Veterans
por: Mayr, Florian B, et al.
Publicado: (2022)

Variation in Clinical Treatment and Outcomes by Race Among US Veterans Hospitalized With COVID-19
por: Castro, Alexander D., et al.
Publicado: (2022)

COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods
por: Mayr, Florian B., et al.
Publicado: (2022)

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
por: Accorsi, Emma K., et al.
Publicado: (2022)

Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population
por: Butt, Adeel A, et al.
Publicado: (2022)

Homologous and Heterologous Covid-19 Booster Vaccinations
por: Atmar, Robert L., et al.
Publicado: (2022)

Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster vaccination
por: Vadrevu, Krishna Mohan
Publicado: (2023)

Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster – authors' reply
por: Rose, Winsley, et al.
Publicado: (2023)

AEs after homologous versus heterologous COVID-19 booster
Publicado: (2022)

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
por: Ranzani, Otavio T., et al.
Publicado: (2022)

Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population
por: Butt, Adeel A., et al.
Publicado: (2021)

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
por: Rouco, Santiago Oviedo, et al.
Publicado: (2022)

Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine
por: Rzymski, Piotr, et al.
Publicado: (2022)

2219. Treatment Uptake for Hepatitis C Virus Infection in the Veterans Affairs Healthcare System in the Era of Directly Acting Antiviral Agents: An ERCHIVES Study
por: Butt, Adeel Ajwad, et al.
Publicado: (2018)

Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination
por: Butt, Adeel A., et al.
Publicado: (2021)

Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations
por: Wei, Yunhua, et al.
Publicado: (2022)

Understanding the complex host response in sepsis: is diabetes the key?
por: Mayr, Florian B., et al.
Publicado: (2016)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

Arguing for Adaptive Clinical Trials in Sepsis
por: Talisa, Victor B., et al.
Publicado: (2018)

Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant
por: Tay, Matthew Zirui, et al.
Publicado: (2023)

514. Nirmatrelvir/ritonavir or Molnupiravir for Treatment of Non-hospitalized Patients with COVID-19 at Risk of Disease Progression
por: Butt, Adeel A, et al.
Publicado: (2023)

Safety Profile of Homologous and Heterologous Booster COVID-19 Vaccines in Physicians in Quito-Ecuador: A Cross-Sectional Study
por: Flores-Lastra, Nancy, et al.
Publicado: (2023)

Booster vaccines for COVID-19 vaccine breakthrough cases?
por: Nixon, Douglas F, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

COVID-19 booster doses in pregnancy and global vaccine equity
por: Kalafat, Erkan, et al.
Publicado: (2022)

WHO prequalified tocilizumab and vaccine boosters against COVID-19
por: Rahimi, Farid, et al.
Publicado: (2022)

Booster vaccinations protect shipboard personnel from COVID-19
por: Ryan, Margaret, et al.
Publicado: (2022)

Is ipsilateral administration of COVID-19 vaccine boosters the optimal approach?
por: Ziegler, Laura, et al.
Publicado: (2023)

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Booster vaccines for COVID-19 vaccine breakthrough cases? – Authors' reply
por: Krause, Philip R, et al.
Publicado: (2022)

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
por: Tan, C. Sabrina, et al.
Publicado: (2022)

Homologous or Heterologous COVID-19 Booster Regimens Significantly Impact Sero-Neutralization of SARS-CoV-2 Virus and Its Variants
por: Buathong, Rome, et al.
Publicado: (2022)

Epidemiology of severe sepsis
por: Mayr, Florian B, et al.
Publicado: (2014)

Heterologous mRNA-based COVID-19 booster strategies: Comment
por: Yasri, Sora, et al.
Publicado: (2023)

Effectiveness of Heterologous COVID-19 Vaccine Booster in Korean Elderly Population, 2022
por: Park, Seon Kyeong, et al.
Publicado: (2023)

Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines Against COVID-19 Hospitalizations: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Do health-care workers need a COVID-19 vaccine booster?
por: Cirillo, Nicola
Publicado: (2022)

Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients
por: Honfi, Dániel, et al.
Publicado: (2022)

Does the homologous booster with the inactivated coronavirus disease 2019 vaccine work for the omicron variant? Real-world evidence from Jilin, China
por: Guo, Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1ojhd78ou6rn60sv6capkd381p